Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AS 101

Drug Profile

AS 101

Alternative Names: AS101; CB-06-02; IVAX-Q-101; IVX-Q-101; Ossirene; WAX-120337

Latest Information Update: 09 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bar-Ilan University
  • Developer BioMAS; Cassiopea; Feramda
  • Class Antineoplastics; Antipsoriatics; Antivirals; Infertility therapies; Nitrogen compounds; Organometallic compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators; Integrin alpha4beta1 antagonists; Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Genital warts
  • Phase I/II Wet age-related macular degeneration
  • Discontinued Acute myeloid leukaemia; Atopic dermatitis; Chemotherapy-induced damage; Female infertility; HIV infections; Male infertility; Myelodysplastic syndromes; Neurological disorders; Psoriasis; Thrombocytopenia

Most Recent Events

  • 09 Jul 2019 Phase II for Genital warts is still ongoing in Israel (Cassiopea's pipeline - July 2019)
  • 09 Jul 2019 BioMAS completes a phase II trial in Genital warts in Israel (Topical, Gel) before July 2019 (NCT01943630)
  • 23 Jul 2018 Cassiopea intends to launch CB 06-02 in 2022
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top